OncoMatch/Clinical Trials/NCT07393542
A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma
Is NCT07393542 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including SHR-A2102 and Adebrelimab and Gemcitabine and cisplatin / carboplatin for locally advanced or metastatic urothelial carcinoma.
Treatment: SHR-A2102 and Adebrelimab · Gemcitabine and cisplatin / carboplatin — The study is being conducted to evaluate the efficacy of SHR-A2102 with adebrelimab versus gemcitabine in combination with cisplatin/carboplatin in previously untreated locally advanced or metastatic urothelial carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Biomarker criteria
Required: NECTIN4 expression testing required (testing required; no eligibility threshold specified)
Able to provide archived or fresh tumor tissue for Nectin-4 and PD-L1 expression.
Required: PD-L1 (CD274) expression testing required (testing required; no eligibility threshold specified)
Able to provide archived or fresh tumor tissue for Nectin-4 and PD-L1 expression.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: antibody-drug conjugate targeting NECTIN4
Previously received therapy with an antibody-drug conjugate that meets any one of the following characteristics: targeting Nectin-4
Cannot have received: antibody-drug conjugate containing irinotecan or its derivatives and acting as a topoisomerase I inhibitor
Previously received therapy with an antibody-drug conjugate that meets any one of the following characteristics: containing irinotecan or its derivatives and acting as a topoisomerase I inhibitor
Cannot have received: immune checkpoint inhibitor
Prior treatment with immune checkpoint inhibitors.
Cannot have received: systemic anti-tumor treatment
Have received systemic anti-tumor treatment within 4 weeks
Cannot have received: anti-tumor Chinese patent medicine
have received prior anti-tumor Chinese patent medicine treatment within 2 weeks
Cannot have received: palliative radiotherapy or local therapy
palliative radiotherapy or local therapy within 2 weeks
Lab requirements
Blood counts
Adequate organ functions.
Kidney function
Adequate organ functions.
Liver function
Adequate organ functions.
Adequate organ functions.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify